PROSTVAC
PROSTVAC (pronounced: pros-t-vac) is a therapeutic vaccine that is currently under investigation for the treatment of prostate cancer. It is designed to stimulate the body's immune system to attack prostate cancer cells.
Etymology
The term "PROSTVAC" is an acronym derived from "PROState" and "VACcine", indicating its primary use in the treatment of prostate cancer.
Usage
PROSTVAC is used in clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC). It is designed to stimulate an immune response against prostate-specific antigen (PSA) expressing cells.
Mechanism of Action
PROSTVAC works by stimulating the body's immune system to attack prostate cancer cells. It uses a virus vector to deliver a gene that codes for PSA, a protein that is overexpressed in prostate cancer cells. This causes the immune system to recognize and attack cells that express PSA.
Related Terms
- Prostate Cancer: A type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.
- Metastatic Cancer: Cancer that has spread from the place where it first started to another place in the body.
- Castration-resistant Prostate Cancer: Prostate cancer that continues to grow despite the suppression of male hormones that fuel the growth of prostate cancer cells.
- Prostate-specific Antigen: A protein produced by cells of the prostate gland. The PSA test measures the level of PSA in a man’s blood.
External links
- Medical encyclopedia article on PROSTVAC
- Wikipedia's article - PROSTVAC
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski